Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. [electronic resource]
Producer: 20110809Description: 484-7 p. digitalISSN:- 1600-0609
- Alkaline Phosphatase -- blood
- Antineoplastic Agents -- therapeutic use
- Boronic Acids -- therapeutic use
- Bortezomib
- Drug Resistance, Neoplasm
- Female
- Humans
- Male
- Middle Aged
- Multiple Myeloma -- drug therapy
- Oligopeptides -- therapeutic use
- Osteogenesis -- drug effects
- Protease Inhibitors -- therapeutic use
- Proteasome Inhibitors
- Pyrazines -- therapeutic use
- Retrospective Studies
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article
There are no comments on this title.
Log in to your account to post a comment.